Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$22.09
+0.1%
$19.85
$10.96
$23.24
$1.14B2.49706,979 shs412,112 shs
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$30.37
-1.6%
$32.09
$21.73
$37.54
$1.06B1.29274,849 shs246,497 shs
Personalis, Inc. stock logo
PSNL
Personalis
$10.73
-3.7%
$6.95
$3.84
$11.85
$1.12B2.281.81 million shs2.20 million shs
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$3.05
-4.7%
$3.63
$2.78
$5.75
$313.38M0.5978,929 shs72,608 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-3.20%+2.46%+2.65%+15.79%+29.22%
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
-3.56%-9.02%-1.41%-7.99%+7.04%
Personalis, Inc. stock logo
PSNL
Personalis
-1.07%+24.61%+92.73%+24.75%+130.64%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
-0.31%+2.56%-3.32%-16.01%-31.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$22.09
+0.1%
$19.85
$10.96
$23.24
$1.14B2.49706,979 shs412,112 shs
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$30.37
-1.6%
$32.09
$21.73
$37.54
$1.06B1.29274,849 shs246,497 shs
Personalis, Inc. stock logo
PSNL
Personalis
$10.73
-3.7%
$6.95
$3.84
$11.85
$1.12B2.281.81 million shs2.20 million shs
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$3.05
-4.7%
$3.63
$2.78
$5.75
$313.38M0.5978,929 shs72,608 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-3.20%+2.46%+2.65%+15.79%+29.22%
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
-3.56%-9.02%-1.41%-7.99%+7.04%
Personalis, Inc. stock logo
PSNL
Personalis
-1.07%+24.61%+92.73%+24.75%+130.64%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
-0.31%+2.56%-3.32%-16.01%-31.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CareDx, Inc. stock logo
CDNA
CareDx
2.00
Hold$25.0013.17% Upside
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
2.88
Moderate Buy$39.0028.42% Upside
Personalis, Inc. stock logo
PSNL
Personalis
2.57
Moderate Buy$11.002.54% Upside
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
2.33
Hold$8.50178.69% Upside

Current Analyst Ratings Breakdown

Latest SBC, PSNL, CDNA, and PNTG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2026
CareDx, Inc. stock logo
CDNA
CareDx
Reiterated RatingSell (D)
5/22/2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
UpgradeHold (C+)Buy (B-)
5/22/2026
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
DowngradeHold (C-)Sell (D+)
5/12/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetEqual Weight$10.00 ➝ $9.00
5/11/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetBuy$13.00 ➝ $11.00
5/8/2026
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
UpgradeSell (D+)Hold (C-)
5/8/2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
Boost Price TargetBuy$36.00 ➝ $42.00
5/8/2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
Boost Price TargetOutperform$41.00 ➝ $42.00
5/8/2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
Boost Price TargetOverweight$38.00 ➝ $41.00
5/7/2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
DowngradeBuy (B-)Hold (C+)
4/29/2026
CareDx, Inc. stock logo
CDNA
CareDx
Boost Price TargetBuy$26.00 ➝ $28.00
(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M3.00$0.01 per share3,500.48$5.89 per share3.75
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$947.71M1.11$1.22 per share24.97$10.82 per share2.81
Personalis, Inc. stock logo
PSNL
Personalis
$69.65M16.13N/AN/A$2.94 per share3.65
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$173.61M1.80$0.50 per share6.14$2.57 per share1.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M-$0.16N/A73.63N/A-2.01%-2.65%-1.96%8/5/2026 (Estimated)
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$29.58M$0.8535.8222.662.152.96%10.07%4.23%8/5/2026 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$81.27M-$1.02N/AN/AN/A-148.11%-43.52%-32.92%8/4/2026 (Estimated)
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$50.99M$0.397.836.22N/A24.09%15.90%11.61%8/12/2026 (Estimated)

Latest SBC, PSNL, CDNA, and PNTG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$0.10$0.11+$0.01$0.11$41.66 million$43.06 million
5/7/2026Q1 2026
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.29-$0.06-$0.29$14.49 million$15.47 million
5/6/2026Q1 2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$0.31$0.32+$0.01$0.24$280.75 million$285.36 million
4/28/2026Q1 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.11$0.34+$0.23$0.05$102.03 million$117.70 million
3/27/2026Q4 2025
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$0.13$0.14+$0.01$0.14$45.19 million$39.57 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CareDx, Inc. stock logo
CDNA
CareDx
N/A
3.40
3.07
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
0.42
1.19
1.19
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.61
6.44
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
0.12
3.82
3.78

Institutional Ownership

CompanyInstitutional Ownership
CareDx, Inc. stock logo
CDNA
CareDx
N/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
85.88%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
60.82%

Insider Ownership

CompanyInsider Ownership
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
6.90%
Personalis, Inc. stock logo
PSNL
Personalis
4.20%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
81.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
CareDx, Inc. stock logo
CDNA
CareDx
74051.66 million50.42 millionOptionable
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
9,70034.77 million32.37 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
400104.72 million100.32 millionOptionable
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
N/A102.58 million18.77 millionN/A

Recent News About These Companies

SBC Medical Group Q1 Earnings Call Highlights
SBC Medical to Announce 1Q 2026 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

CareDx stock logo

CareDx NASDAQ:CDNA

$22.09 +0.02 (+0.09%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

The Pennant Group stock logo

The Pennant Group NASDAQ:PNTG

$30.37 -0.49 (-1.59%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Personalis stock logo

Personalis NASDAQ:PSNL

$10.73 -0.41 (-3.71%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

SBC Medical Group stock logo

SBC Medical Group NASDAQ:SBC

$3.05 -0.15 (-4.69%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.